Distant recurrence-free survival of postmenopausal, oestrogen-receptor-positive breast cancer patients with genotypes linked to the benefit from adjuvant tamoxifen therapy

<p><b>Copyright information:</b></p><p>Taken from "Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients"</p><p>Breast Cancer Research 2005;7(3):R284-R290.</p><p>Published online 28 Jan 2005</p><p>PMCID:PMC1143572.</p><p>Copyright © 2005 Wegman et al., licensee BioMed Central Ltd.</p> Solid line, patients treated with tamoxifen (Tam+); dashed line, patients not receiving adjuvant tamoxifen therapy (Tam-). Patients homozygous for the allele and/or homozygous or heterozygous for the allele. The number of events for Tam+ and Tam- were 15 and 27, respectively. Patients homozygous for the allele and homozygous or heterozygous for the allele. The number of events for Tam+ and Tam- were 15 and 18, respectively. The relative risk for distant recurrence was calculated for each genotype; when compared, a significant decrease in relative risk was found for the beneficial genotypes (= 0.018)